Summit TherapeuticsSMMT
SMMT
About: Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Employees: 159
0
Funds holding %
of 7,419 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
168% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 25
97% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 38
22% more funds holding
Funds holding: 165 [Q3] → 202 (+37) [Q4]
0.89% more ownership
Funds ownership: 11.66% [Q3] → 12.55% (+0.89%) [Q4]
11% less capital invested
Capital invested by funds: $1.85B [Q3] → $1.65B (-$196M) [Q4]
32% less call options, than puts
Call options by funds: $36.7M | Put options by funds: $53.9M
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$30
12%
downside
Avg. target
$37
8%
upside
High target
$44
30%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
Citigroup Yigal Nochomovitz 15% 1-year accuracy 6 / 41 met price target | 3%upside $35 | Buy Upgraded | 26 Mar 2025 |
Evercore ISI Group Cory Kasimov 35% 1-year accuracy 6 / 17 met price target | 12%downside $30 | Outperform Initiated | 12 Mar 2025 |
Goldman Sachs Salveen Richter 16% 1-year accuracy 3 / 19 met price target | 24%upside $42 | Buy Initiated | 28 Feb 2025 |
Citizens Capital Markets Reni Benjamin 15% 1-year accuracy 6 / 40 met price target | 6%downside $32 | Market Outperform Reiterated | 25 Feb 2025 |
HC Wainwright & Co. Mitchell Kapoor 30% 1-year accuracy 55 / 185 met price target | 30%upside $44 | Buy Reiterated | 25 Feb 2025 |
Financial journalist opinion
Based on 14 articles about SMMT published over the past 30 days
Positive
The Motley Fool
21 hours ago
Why Summit Therapeutics Rocketed Double-Digits Today
Shares of lung cancer biotech Summit Therapeutics (SMMT 21.72%) rocketed 14.7% on Wednesday as of 1:45 p.m. ET.
Positive
Benzinga
22 hours ago
Why Is Summit Therapeutics Stock Soaring On Wednesday?
Summit Therapeutics Inc.'s SMMT partner, Akeso, Inc., released topline data from the Phase 3 HARMONi-6/K112-306 trial on Wednesday.
Neutral
Business Wire
1 day ago
Ivonescimab in Combination with Chemotherapy Achieves Statistically Significant Superiority in PFS vs. Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in HARMONi-6 Study Conducted by Akeso in China
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today noted that Akeso, Inc. (Akeso, HKEX Code: 9926.HK) announced that the Phase III clinical trial, HARMONi-6 or AK112-306, met its primary endpoint of progression-free survival (PFS). HARMONi-6 is evaluating ivonescimab in combination with platinum-based chemotherapy compared with tislelizumab, a PD-1 inhibitor, in combination with platinum-based chemotherapy in patients with locally advanced o.
Positive
The Motley Fool
1 day ago
This Company's Co-CEOs Just Bought More Shares. Should You?
Nobody has more information about a company than its insiders, especially its executive management team. That's why when one of them buys more shares, it sometimes gives individual investors insights into the company's prospects.
Neutral
Seeking Alpha
1 week ago
Summit Therapeutics: Multibillion Dollar NSCLC Potential Faces Growing Competition
Summit Therapeutics' ivonescimab shows promising results in China, outperforming Keytruda in PD-L1 positive advanced NSCLC, with potential $10 billion peak annual revenue. Fierce competition exists in the PD-1/VEGF bispecific antibody space, with major players like Merck and BioNTech entering the market. Summit's financial health shows a significant cash runway into late 2027, despite high R&D and G&A expenses and no revenue generation.
Positive
The Motley Fool
1 week ago
3 Magnificent Stocks That Could Double or More by 2030
When the stock market is as turbulent as it is these days, it's easy to forget the times when things are decidedly more cheery. However, sell-offs present great opportunities to buy stocks with significant upside potential.
Positive
The Motley Fool
1 week ago
Why Summit Therapeutics Rallied Double Digits Today on Another Down day for the Markets
Shares of lung cancer-focused biotech Summit Therapeutics (SMMT 10.72%) rallied 16.6% at its highs of the day before settling into a 10.4% gain on Thursday as of 3:54 p.m. EDT, even though the broader markets were down significantly on the day at that time, including the SPDR S&P Biotech ETF (XBI -4.37%), which was down 4.4%.
Neutral
The Motley Fool
2 weeks ago
2 Stocks That Have More Than Doubled in the Past Year to Buy and Hold for a Decade
Equity markets recently dipped due to concerns of deteriorating macroeconomic conditions, with the latest trigger being President Trump's trade wars. The S&P 500 index's performance over the trailing-12-month period no longer looks quite as impressive as it did at the start of 2025 -- the equity index is down nearly 1.5% over this period.
Neutral
Business Wire
2 weeks ago
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of up to 176,915 shares of common stock. Awards were made to ten (10) new employees of the Company. The awards were granted as an inducement material to the new employees becoming employees of the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and have been approved by the Company's Compensation Com.
Positive
The Motley Fool
3 weeks ago
3 Growth Stocks That Have Dwarfed Nvidia's Returns Over the Past 12 Months
Is the excitement surrounding chipmaker Nvidia fading? As of Monday, shares of the tech giant were down 19% since the start of 2025.
Charts implemented using Lightweight Charts™